inhalation formulation services

Inhaled drug products for nasal or pulmonary delivery continue in popularity due to the prevalence of respiratory diseases around the globe. Additionally, the lung’s absorptive capacity continues to be explored as an attractive delivery point for both local and systemic applications. Particle engineering, a core strength of Lonza, is critical in achieving the particle size distribution required for effective drug delivery using dry powder inhaler (DPI) devices.

DPI technology has become the preferred approach for inhalation formulation vs. other dry powder technologies or aerosols. Lactose-blend or carrier-free based approaches to DPI require precise particle engineering through either micronization / jet milling or spray drying, respectively. Expertise and depth of capabilities in both particle size reduction and spray drying allows our scientists to choose the most appropriate technology for your specific DPI application.

Our premier particle engineering platform is complemented by a full range of product development. Our product development teams are well versed in powder performance parameters for capsule-based devices. Our customers benefit from a flexible, integrated service offering inclusive of API development, API characterization and assessment, technology selection, particle engineering, formulation development, specialized analytical method development, and the manufacture of encapsulated DPI formulations at development, clinical and commercial scale. Phase-appropriate jet mills and spray dryers are in place to facilitate rapid proof of concept evaluations, cGMP clinical trial manufacture and commercialization.